News Releases

Text size
view with small font size
view with medium font size
view with large font size


2019July NEW!Kyowa Hakko Kirin Co.,Ltd changed company name to Kyowa Kirin Co.,Ltd and changed its new logo at the same time. As a member of the group,KKCN launched the new LOGO on July 1
2017MayTransferring the selling right of CONIEL in the Chinese market to Winhealth Pharma Group
2017FebREGPARA included in NRDL
2015NovCompletion of construction of a new facility for the manufacture of tablets
2015FebREGPARA was launched in China
2014JulyREGPARA acquired IDL
2013JulyCompletion of construction of a new facility for the manufacture of in-vitro diagnostic reagents.
2013AprilTransferring the selling right of Busulfex in the Chinese market to Otsuka Pharmaceutical(ZheJiang) Co., Ltd.
2012KKCNRenaming the company "Kyowa Hakko Kirin China Pharmaceutical Co., Ltd.(KKCN)"officially.
2011KKCLAs the local legal enterprise of Kyowa Hakko Kirin Co., Ltd.(KHK), Kirin Kunpeng (China)Bio-Pharmaceutical Co., Ltd.(KKCL) was merged with Kyowa Hakko Pharmaceutical Technology(Shanghai) Co., Ltd(KH).
2010KHAllelock was launched in China.
2010KKCLKirin Kunpeng (China) Bio-Pharmaceutical Co., Ltd.(KKCL) has become a wholly-owned subsidiary which is 100% funded by the Kyowa Hakko Kirin Group (KHK)
2008KHKyowa Hakko Pharmaceutical Technology (Shanghai) Co., Ltd(KH)was established.
2005KYOWAKyowa Hakko Kogyo Co., Ltd. Guangzhou Representative Office was established.
2005KKCLBusulfex was launched in China.
2005KYOWAConiel was launched in China.
2001KKCLSelling domestic Gran and Espo in China.
1997KKCLKirin Kunpeng (China) Bio-Pharmaceutical Co., Ltd.(KKCL) was established.
1996KIRINEspo was launched in China.
1994KIRINGran was launched in China.
1993KIRINKirin Pharmaceuticals (China) Co., Ltd was established.
1991KYOWAKyowa Hakko Kogyo Co., Ltd. Shanghai Representative Office was established.
1988KYOWAKyowa Hakko Kogyo Co., Ltd. Beijing Representative Office was established.
1982KIRINInvesting in the research and development of biotechnological drugs as the main direction.